The third Risk Sharing Agreement (RSA) contract for Erbitux, a treatment for metastatic direct bowel cancer and cranial cell cancer, is being prolonged. It is known that renegotiations have been underway since the first round of negotiations with the National Health Insurance Service broke down. Erbitux's second RSA contract period has ended as of June last year.

According to the corporation and the industry on the 7th, Merck and the NHIS are negotiating for a third contract as Erbitux's renewal of RSA has ended. Erbitux signed its first RSA for Refund contract in 2014. And after four years of the contract, he succeeded in renewing his contract in 2018. It was the first case of renewal as an RSA drug. T